PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat

V. Bhardwaj, D.D. Ankola, S.C. Gupta, M. Schneider, C.M. Lehr, M.N.V.R. Kumar

Research output: Contribution to journalArticle

114 Citations (Scopus)


Purpose This study was carried out to formulate poly(lactide-co-glycolide) (PLGA) nanoparticles using a quaternary ammonium salt didodecyl dimethylammonium bromide (DMAB) and checking their utility to deliver paclitaxel by oral route. Methods Particles were prepared by emulsion solvent diffusion evaporation method. DMAB and particles stabilized with it were evaluated by MTT and LDH cytotoxicity assays. Paclitaxel was encapsulated in these nanoparticles and evaluated in a chemical carcinogenesis model in Sprague Dawley rats. Results MTT and LDH assays showed the surfactant to be safe to in vitro cell cultures at concentrations <33 μM. PLGA nanoparticles prepared using this stabilizer were also found to be non-toxic to cell lines for the duration of the study. When administered orally to rats bearing chemically induced breast cancer, nanoparticles were equally effective/better than intravenous paclitaxel in cremophor EL at 50% lower dose. Conclusions This study proves the safety and utility of DMAB in stabilizing preformed polymers like PLGA resulting in nanoparticles. This preliminary data provides a proof of concept of enabling oral chemotherapy by efficacy enhancement for paclitaxel.
Original languageEnglish
Pages (from-to)2495-2503
Number of pages9
JournalPharmaceutical Research
Issue number11
Publication statusPublished - Nov 2009



  • breast cancer
  • EPR effect
  • nanoparticles
  • oral drug delivery
  • paclitaxel

Cite this